| Literature DB >> 25834623 |
Yuhe Yan1, Wali Liu1, Philippe Andres2, Colette Pernin2, Laurent Chantalat2, Philippe Briantais2, Albert Lin2, Lilian Feng2.
Abstract
Objective. To evaluate the efficacy and safety of herbal ointment, Shi Du Ruan Gao, in patients with plaque-type psoriasis. Design. Single-center, randomized, investigator-blinded, parallel group, placebo-controlled study. Participants. One hundred outpatients with mild to moderate chronic plaque-type psoriasis were enrolled. Intervention. The patients applied either Shi Du Ruan Gao ointment or vehicle ointment topically to for 8 weeks. Main Outcome Measures. The outcomes were assessed using the following criteria: Total Severity Score (TSS, sum of erythema, scaling, and plaque elevation/induration, on a 0 to 4 scale), Investigator Global Assessment (IGA) evaluated on a 0 (Clear) to 4 (s to very severe) scale, and Global Subjects' Assessment of treatment response on a 7-point scale from -1 (worse) to 5 (Cleared). Results. Significant reductions in the Total Severity Score (P < 0.001) (mean score: 2.7 after Shi Du Ruan Gao treatment versus 5.1 in control subjects). Both Investigator Global Assessment (IGA) and Global Subjects' Assessment of treatment are better in the Shi Du Ruan Gao group than the control group (P < 0.001). Conclusion. Shi Du Ruan Gao ointment was a safe, and effective therapy for plaque-type psoriasis.Entities:
Year: 2015 PMID: 25834623 PMCID: PMC4365322 DOI: 10.1155/2015/719641
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1SHI DU RUAN GAO contains indigo naturalis (Qing Dai), Cortex Phellodendri (Huang Bai), Gypsum fibrosum preparatum (Duan Shi Gao), Calamine (Lu Gan Shi), and Galla chinensis (Wu Bei Zi).
The baseline characteristics of all patients.
| Dimeticone/placebo | Shi Du Ruan Gao | ||
|---|---|---|---|
| Gender |
| 50 | 50 |
| Female | 20 (40) | 16 (32) | |
| Male | 30 (60) | 34 (68) | |
|
| |||
| Age (in years) |
| 50 | 50 |
| <65 years | 50 (100.0) | 50 (100.0) | |
| Mean ± SD | 44.7 ± 12.2 | 46.9 ± 11.3 | |
| Median | 45 | 50 | |
| Min~Max | 22~64 | 21~64 | |
|
| |||
| TSS (baseline) | Mean ± SD | 6.4 ± 1.6 | 6.5 ± 1.3 |
| Median | 6.0 | 6.0 | |
| Min~Max | 3~10 | 4~10 | |
|
| 5~8 | 4~10 | |
Figure 2Clinical photographs of 2 patients with plaque-type psoriasis before, after 4 weeks, and after 8 weeks of treatment with SDRG.
Summary of the TSS at baseline and week 8. (1)Based on an ANCOVA with including the treatment group as factor and TSS at baseline as a covariate.
| Dimeticone/placebo | Shi Du Ruan Gao |
| ||
|---|---|---|---|---|
| Baseline |
| 50 | 50 | |
| Mean ± SD | 6.4 ± 1.6 | 6.5 ± 1.3 | ||
| Median | 6.0 | 6.0 | ||
| Min~Max | 3~10 | 4~10 | ||
|
| 5~8 | 4~10 | ||
|
| ||||
| Week 8 LOCF (ITT) |
| 50 | 50 | <0.001 |
| Mean ± SD | 5.1 ± 2.1 | 2.7 ± 2.2 | ||
| LS-Mean | 5.1 | 2.7 | ||
| Median | 5.0 | 2.0 | ||
| Min~Max | 0~10 | 0~8 | ||
|
| 4~6 | 1~4 | ||
|
| ||||
| Week 8 (PP) |
| 48 | 45 | <0.001 |
| Mean ± SD | 5.0 ± 2.1 | 2.4 ± 2.0 | ||
| LS-Mean | 5.1 | 2.3 | ||
| Median | 5.0 | 2.0 | ||
| Min~Max | 0~10 | 0~8 | ||
|
| 4~6 | 1~3 | ||
|
| 4~6 | 1~3 | ||
Summary of the secondary efficacy criteria (ITT-LOCF). (1)CMH test using row mean score difference statistic and ridit transformation.
| Dimeticone/placebo | Shi Du Ruan Gao |
| ||||
|---|---|---|---|---|---|---|
| Raw data | Change from baseline | Raw data | Change from baseline | Change from baseline | ||
| TSS |
| 50 | 50 | 50 | 50 | <0.001 |
| Mean ± SD | 5.1 ± 2.1 | −1.3 ± 1.4 | 2.7 ± 2.2 | −3.8 ± 1.9 | ||
| Median | 5.0 | −1.0 | 2.0 | −4.5 | ||
| Min~Max | 0~10 | −5~1 | 0~8 | −7~0 | ||
|
| 4~6 | −2~0 | 1~4 | −5~−3 | ||
|
| ||||||
| Erythema |
| 50 | 50 | 50 | 50 | <0.001 |
| Mean ± SD | 1.9 ± 0.8 | −0.3 ± 0.7 | 1.2 ± 0.7 | −1.2 ± 0.7 | ||
| Median | 2.0 | 0.0 | 1.0 | −1.0 | ||
| Min~Max | 0~4 | −2~1 | 0~3 | −2~1 | ||
|
| 1.0~2.0 | −1.0~0.0 | 1.0~2.0 | −2.0~1.0 | ||
|
| ||||||
| Plaque elevation |
| 50 | 50 | 50 | 50 | <0.001 |
| Mean ± SD | 1.7 ± 0.8 | −0.4 ± 0.6 | 0.8 ± 0.9 | −1.5 ± 0.9 | ||
| Median | 2.0 | 0.0 | 0.5 | −2.0 | ||
| Min~Max | 0~3 | −2~1 | 0~3 | −3~0 | ||
|
| 1.0~2.0 | −1.0~0.0 | 0.0~1.0 | −2.0~1.0 | ||
|
| ||||||
| Scaling |
| 50 | 50 | 50 | 50 | <0.001 |
| Mean ± SD | 1.5 ± 0.9 | −0.6 ± 0.8 | 0.8 ± 0.9 | −1.1 ± 0.8 | ||
| Median | 1.0 | 0.0 | 1.0 | −1.0 | ||
| Min~Max | 0~4 | −2~1 | 0~3 | −3~0 | ||
|
| 1.0~2.0 | −1.0~0.0 | 0.0~1.0 | −2.0~1.0 | ||
Distribution of IGA in terms of success rate at week 8 (ITT-LOCF). Success is defined as subjects having an IGA of 0 = clear or 1 = very mild (1)Chi-square.
| Dimeticone/placebo | Shi Du Ruan Gao |
| ||
|---|---|---|---|---|
| IGA at week 8, LOCF |
| 50 (100) | 50 (100) | <0.001 |
| Success | 12 (24.0) | 36 (72.0) | ||
| Failure | 38 (76.0) | 14 (28.0) |
Subjects' Global Assessment of Improvement (observed cases). (1)CMH test using row mean score difference statistic and ridit transformation.
| Dimeticone/placebo | Shi Du Ruan Gao |
| ||
|---|---|---|---|---|
| Final visit (observed cases) |
| 48 (100) | 45 (100) | <0.001 |
| −1: worse | 1 (2.1) | |||
| 0: unchanged | 14 (29.2) | 2 (4.4) | ||
| 1: slight | 13 (27.1) | 3 (6.7) | ||
| 2: fair | 14 (29.2) | 11 (24.4) | ||
| 3: good | 4 (8.3) | 11 (24.4) | ||
| 4: excellent | 2 (4.2) | 15 (33.3) | ||
| 5: cleared | 3 (6.7) |
Adverse events are defined as events occurred after the first use of medication. Numbers in columns cannot be added because a given subject may have reported more than one AE.
| MedDRA v 12.0 | Dimeticone/placebo ( | Shi Du Ruan Gao ( | ||
|---|---|---|---|---|
|
|
|
|
| |
| All AEs | 2 | 2 (4.0%) | 0 | 0 (0.0%) |
| Related AEs | 0 | 0 (0.0%) | 0 | 0 (0.0%) |
| All dermatologic AEs | 2 | 2 (4.0%) | 0 | 0 (0.0%) |
| Related dermatologic AEs | 0 | 0 (0.0%) | 0 | 0 (0.0%) |
| All serious AES | 0 | 0 (0.0%) | 0 | 0 (0.0%) |
| Related serious AEs | 0 | 0 (0.0%) | 0 (0.0%) | |
| Severe AEs | 0 | 0 (0.0%) | 0 | 0 (0.0%) |
| Related severe AEs | 0 | 0 (0.0%) | 0 | 0 (0.0%) |
| AEs of special interest | 0 | 0 (0.0%) | 0 | 0 (0.0%) |
| Related AEs of special interest | 0 | 0 (0.0%) | 0 | 0 (0.0%) |
| AEs leading to discontinuation | 0 | 0 (0.0%) | 0 | 0 (0.0%) |
| Related AEs leading to discontinuation | 0 | 0 (0.0%) | 0 | 0 (0.0%) |
| Deaths | 0 | 0 (0.0%) | 0 | 0 (0.0%) |